Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.84 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.84 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.80 |
| ▸ | PDE2A | O00408 | 1/20 | 0.80 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.80 |
| ▸ | PDE6D | O43924 | 1/20 | 0.80 |
| ▸ | PDE8A | O60658 | 1/20 | 0.80 |
| ▸ | PDE9A | O76083 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | PDE6A | P16499 | 1/20 | 0.80 |
| ▸ | PDE6G | P18545 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lodenafil Carbonate SCHEMBL30852274 | 1.00 | PDE5A (0.84) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL5008158 | 0.94 | PDE5A (0.81) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL28542261 | 0.92 | PDE5A (0.86) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| Lodenafil SCHEMBL31202790 | 0.91 | PDE5A (1.00) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| Lodenafil SCHEMBL1058 | 0.91 | PDE5A (1.00) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL30848678 | 0.91 | PDE5A (0.95) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL17390250 | 0.91 | PDE5A (0.83) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL17390175 | 0.91 | PDE5A (0.85) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL5010426 | 0.90 | PDE5A (0.90) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL17342850 | 0.90 | PDE5A (1.00) | PDE5APDE3BPDE3AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-7148350-B2 | Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction | CRISTALIA PROD.QUI.FARM. LTDA (BR) | 2006-12-12 | — | — | US | claimed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4626438-A2 | INHALABLE HORMONE RECEPTOR AGONIST FORMULATIONS | Pinata Holdings Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4536292-A1 | MITOCHONDRIA AS A TARGETED DELIVERY PLATFORM | cellvie AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| US-20250090534-A1 | Phosphodiesterase-5 Inhibitor Combinations, Methods of Making, and Methods of Use Thereof | VK RESEARCH ASSOCIATES INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| CN-119486767-A | Mitochondria as targeted delivery platform | 赛尔维股份公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4486303-A1 | ENTERIC COATED DRY POWDERED CANNABINOID FORMULATIONS | Pinata Holdings Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20250000806-A1 | Dry Powdered Formulations | PINATA HOLDINGS INC. | 2025-01-02 | — | — | US | disclosed |
| EP-2672957-A1 | NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS | SciPharm SàRL (LU) | 2013-12-18 | — | — | EP | disclosed |
| US-20130296331-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-11-07 | — | — | US | disclosed |
| EP-2637664-A2 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION | Gilead Sciences, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013067309-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST COMPOUNDS | XION PHARMACEUTICAL CORPORATION (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20120269898-A1 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. | 2012-10-25 | — | — | US | disclosed |
| WO-2012107363-A1 | NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS | SCIPHARM SÀRL (LU) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012070040-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012051559-A2 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| EP-1315729-B1 | COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PROD QUIMICOS FARM (BR) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | PDE5A 1399/4885PDE3B 2158/4885PDE3A 1915/4885 |
| US-20250000806-A1 | Dry Powdered Formulations | LIPA, ADCYAP1R1, PCSK9 | PDE5A 95/4885PDE3B 131/4885PDE3A 96/4885 |
| US-20120269898-A1 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION | PDE3A, PDE3B, PDE5A | PDE5A 3/4885PDE3B 2/4885PDE3A 1/4885 |
| US-20130296331-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE3B 1/4885PDE3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.